Endoscopic Vessel Harvesting - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Endoscopic Vessel Harvesting Market Analysis

The endoscopic vessel harvesting market size reached USD 522 million in 2025 and is projected to attain USD 632 million by 2030, reflecting a 3.9% CAGR. Growing cardiac surgery volumes, heightened surgeon preference for minimally invasive conduit procurement, and steady product innovation all sustain this measured expansion. Demand remains most intense in high-income regions where value-based care frameworks reward shorter stays and lower complication rates. Hybrid platforms that bundle visualization, insufflation, and disposable kits are gaining traction because they simplify procurement and standardize procedural quality. Meanwhile, recent device recalls are prompting hospitals to scrutinize supplier quality systems more closely, encouraging a flight to vendors with strong post-market surveillance records.

Global Endoscopic Vessel Harvesting Market Trends and Insights

Increasing Global Burden of Cardiovascular Diseases

Cardiovascular pathology affects nearly half of U.S. adults and continues to climb in many emerging economies. Growing procedure volumes make efficient conduit harvesting a strategic necessity for surgical programs managing tight bed capacity and readmission penalties. Hospitals adopting endoscopic techniques report fewer wound infections and faster ambulation, outcomes that align with modern bundled-payment incentives. The burden remains particularly high among aging cohorts with diabetes and hypertension, reinforcing the need for durable grafts and low-morbidity access sites. Governments are channeling funds into cardiac centers of excellence, catalyzing procurement of integrated EVH platforms that promise predictable learning curves and reduced staff turnover. Vendors able to document long-term graft patency and cost offsets stand to benefit most from these epidemiological tailwinds.

Growing Preference for Minimally-Invasive Harvesting

Prospective data show leg wound complications of 0.82% with endoscopic approaches versus 3% for open extraction. Patient-reported outcome measures consistently favor minimal scarring and quicker mobility, metrics now embedded in many pay-for-performance dashboards. Hospitals marketing “scar-sparing” programs gain reputational lift that translates into higher referral volumes, especially in competitive urban catchments. Widespread adoption of virtual-reality simulation has shortened operator learning curves and cut fluoroscopy exposure times by nearly one-third. Nonetheless, centers must invest in structured mentorship to avoid early complication clusters that can erode surgeon confidence. Device designers are responding with ergonomic handles and automated cutting controls to further flatten proficiency curves.

Availability of Alternative Revascularization Therapies

Rapid improvements in complex percutaneous coronary intervention techniques are siphoning off some multi-vessel cases that once defaulted to coronary artery bypass grafting. Although CABG retains superiority in diabetics and diffuse disease, declining open-heart volumes in certain geographies could curb EVH unit sales. Yet, the remaining surgical cases now skew toward higher-risk profiles where minimally invasive conduit harvest offers outsized benefits. Device makers therefore position EVH as a precision tool for the subset of patients who still require grafts, emphasizing patency and wound-healing advantages versus open techniques.

Other drivers and restraints analyzed in the detailed report include:

1. Rising Adoption of Off-Pump CABG Surgeries
2. Hospitals’ Cost-Saving Shift from Open to EVH
3. Unfavorable Reimbursement in Several Countries

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

EVH systems generated USD 346 million in 2024, equal to 66.35% of the endoscopic vessel harvesting market. Hospitals purchase these capital assets once every 5-7 years, locking equipment vendors into multiyear service contracts. The accessories and disposables category, though smaller in absolute value, is growing at an 8.25% CAGR thanks to its annuity-style revenue that aligns with procedure counts. Bundled kits containing blades, scopes, and CO₂ lines simplify case setup and ensure compatibility, a convenience that purchasing managers value.

Recurring consumables are particularly attractive to ambulatory surgical centers that lack onsite sterilization capacity. Meanwhile, competitive differentiation among capital systems now hinges on image resolution, ergonomic handpieces, and analytics dashboards that log usage statistics for credentialing purposes. Getinge’s Hemopro 3 rollout exemplifies this pivot toward safety-enhanced systems designed to reassure surgeons following prior recalls.

Radial artery conduits captured 42.53% of 2024 volume owing to superior 10-year patency, especially in younger and diabetic patients. Surgeons increasingly adopt bilateral radial strategies, boosting system utilization. Conversely, saphenous vein grafting remains indispensable when three or more distal targets must be bypassed, explaining its projected 7.85% CAGR. Evidence supporting no-touch, perivascular-preserving harvest has mitigated early skepticism regarding vein quality.

Device vendors are developing slimmer scopes and lower-pressure insufflation protocols to reduce endothelial trauma, thereby appealing to skeptics who still prefer open harvest for long conduits. Hospitals now run parallel workflows: radial for high-patency needs and optimized saphenous for multi-graft cases, a trend that increases demand for versatile system platforms.

The Endoscopic Vessel Harvesting Market Report is Segmented by Product (EVH Systems and More), Vessel Type (Saphenous Vein and More), Usability (Disposable and Reusable), Application (Coronary Artery Disease and Peripheral Artery Disease), End-User (Hospitals and More), Harvesting Technique (Closed-Tunnel CO₂ Insufflation and No-Touch), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America generated 42.82% of 2024 turnover, underpinned by robust reimbursement and high procedural density across academic centers and community hospitals. CMS coverage consistently endorses EVH when clinically justified, and bundled-payment pilots reward shorter length of stay. Ongoing FDA engagement, including 510(k) clearances for upgraded systems, keeps innovation pipelines active. Training consortia such as STS and AATS integrate EVH modules into resident curricula, reinforcing widespread competence.

Europe follows with steady uptake driven by data-driven protocols and cross-border trials. Yet, budget caps in single-payer systems delay refresh cycles, compelling vendors to emphasize cost-utility. Scandinavian hospitals pioneered reusable scopes to satisfy environmental directives, a model now emulated in Germany and France. Mediterranean health systems, facing constrained capital budgets, gravitate toward service-leasing contracts that convert upfront equipment outlays into per-procedure fees.

Asia-Pacific is the fastest-growing territory at 10.13% CAGR through 2030, fueled by Japan’s aging population, China’s expanding middle class, and government investments in tertiary cardiac centers. Japanese surgeons have embraced totally endoscopic robotic harvests, setting performance benchmarks admired across the region. Chinese regulators increasingly fast-track cardiac devices deemed essential to public-health goals, but provincial reimbursement remains uneven. India and Southeast Asia show latent demand limited by training bottlenecks; therefore, vendors partner with medical colleges to build harvesting fellowships.

South America records moderate growth, spearheaded by Brazil’s public-private hospital network that undertakes high-volume CABG. Import taxes and currency volatility challenge foreign entrants, encouraging localized production partnerships. The Middle East and Africa present niche opportunities tied to flagship cardiac institutes in the Gulf and South Africa, yet widespread adoption is hampered by limited insurance coverage and surgeon shortages.

List of Companies Covered in this Report:

1. Getinge
2. Terumo Corp.
3. LivaNova
4. Karl Storz
5. Saphena Medical Inc.
6. Medical Instruments SpA
7. Medtronic
8. Olympus Corp.
9. Conmed
10. B. Braun
11. Cardio Medical GmbH
12. Valeriot GmbH
13. LeMaitre Vascular
14. Boston Scientific
15. Ethicon (J&J)
16. Smiths Group
17. Stryker
18. Teleflex
19. CardiMedical Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support